Speaker illustration

Associate Professor David Preiss

University of Oxford, Oxford (United Kingdom of Great Britain & Northern Ireland)

Member of:

European Society of Cardiology

David Preiss is a clinical academic with qualifications as a Chemical Pathologist and a Metabolic Physician. He joined the Clinical Trial Service Unit, Oxford, in 2015. His major interests are the prevention of cardiovascular disease (CVD) and also microvascular complications of diabetes, with particular focus on lipid modification and glucose lowering. He is Chief Investigator for the LENS trial, testing the effect of fenofibrate on diabetic retinopathy progression. He is also Co-Principal Investigator on the EMPA-KIDNEY trial (SGLT2 inhibition in patients with chronic kidney disease) and Clinical Coordinator for the ORION-4 trial (PCSK9 synthesis inhibition in a secondary prevention population). He was awarded the University of Glasgow’s Bellahouston Medal for his PhD thesis which examined the links between glycaemia and CVD. He is a previous recipient of a EFSD Rising Star fellowship and also of the Royal College of Pathology’s Research Medal for Clinical Biochemistry.

New ways of lowering lipids.

Event: ESC Congress 2019

Topic: Drug therapy

Session: Evolving concepts in lipidology


Benefits and harms of fibrates.

Event: ESC Congress 2019

Topic: Pharmacology and Pharmacotherapy

Session: Targeting triglycerides to prevent coronary artery disease


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb